相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Chitosan nanoparticles as a dual drug/siRNA delivery system for treatment of colorectal cancer
Sanam Sadreddini et al.
IMMUNOLOGY LETTERS (2017)
DGK-alpha: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy
Elfriede Noessner
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2017)
Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy
Zahra Valedkarimi et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Immune checkpoint receptors in cancer: redundant by design?
Jing Li et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
Jae H. Park et al.
BLOOD (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4+ T Cell Immunity
Deshapriya S. Karunarathne et al.
IMMUNITY (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
Diacylglycerol Kinase ζ Is a Target To Enhance NK Cell Function
Enjun Yang et al.
JOURNAL OF IMMUNOLOGY (2016)
B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer
Hong Xu et al.
ONCOLOGY LETTERS (2016)
B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy
Juan Ma et al.
ONCOTARGET (2016)
Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer
Matthew J. Riese et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2016)
Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases: An Update
Fumio Sakane et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2016)
Phage display as a promising approach for vaccine development
Leili Aghebati-Maleki et al.
JOURNAL OF BIOMEDICAL SCIENCE (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
Edgardo D. Carosella et al.
EUROPEAN UROLOGY (2015)
Blockade of PD1 and TIM3 Restores Innate and Adaptive Immunity in Patients With Acute Alcoholic Hepatitis
Lee J. L. Markwick et al.
GASTROENTEROLOGY (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
Abhisek Swaika et al.
MOLECULAR IMMUNOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Jun Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response
Jung-Tsu Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
Kyoung Wan Yoon et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Drew Pardoll
SEMINARS IN ONCOLOGY (2015)
Apoptosis of tumor infiltrating effector TIM-3+CD8+T cells in colon cancer
Chiao-Wen Kang et al.
SCIENTIFIC REPORTS (2015)
Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Theodore Kouo et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
John Powderly et al.
Journal for ImmunoTherapy of Cancer (2015)
PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment
Jing Li et al.
CANCER RESEARCH (2015)
Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
George K. Philips et al.
INTERNATIONAL IMMUNOLOGY (2015)
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang et al.
NATURE (2015)
The ins and outs of MHC class II-mediated antigen processing and presentation
Paul A. Roche et al.
NATURE REVIEWS IMMUNOLOGY (2015)
VISTA Is an Immune Checkpoint Molecule for Human T Cells
J. Louise Lines et al.
CANCER RESEARCH (2014)
VISTA Regulates the Development of Protective Antitumor Immunity
Isabelle Le Mercier et al.
CANCER RESEARCH (2014)
Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2014)
NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention
Petra U. Prinz et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Overexpression of B7-H3 in CD14+ monocytes is associated with renal cell carcinoma progression
Miao Li et al.
MEDICAL ONCOLOGY (2014)
Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation
Emanuela I. Sega et al.
PLOS ONE (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
Edward Cha et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
T and NK cells: two sides of tumor immunoevasion
Doriana Fruci et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
B7-H3 expression in ductal and lobular breast cancer and its association with IL-10
Chuanyong Liu et al.
MOLECULAR MEDICINE REPORTS (2013)
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
Nicola Gagliani et al.
NATURE MEDICINE (2013)
Characterization of a Soluble B7-H3 (sB7-H3) Spliced from the Intron and Analysis of sB7-H3 in the Sera of Patients with Hepatocellular Carcinoma
Weiwei Chen et al.
PLOS ONE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Tim-3: an activation marker and activation limiter of innate immune cells
Gencheng Han et al.
FRONTIERS IN IMMUNOLOGY (2013)
HMGB1: the central cytokine for all lymphoid cells
Guanqiao Li et al.
FRONTIERS IN IMMUNOLOGY (2013)
Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer
Sandip P. Patel et al.
CURRENT COLORECTAL CANCER REPORTS (2013)
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9
Michelle K. Gleason et al.
BLOOD (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity
Deryk Loo et al.
CLINICAL CANCER RESEARCH (2012)
Tim-3, a negative regulator of anti-tumor immunity
Ana Carrizosa Anderson
CURRENT OPINION IN IMMUNOLOGY (2012)
Immune checkpoints in central nervous system autoimmunity
Nicole Joller et al.
IMMUNOLOGICAL REVIEWS (2012)
Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
Yishan Liu et al.
INTERNATIONAL JOURNAL OF UROLOGY (2012)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Tumor immunity times out: TIM-3 and HMGB1
Daolin Tang et al.
NATURE IMMUNOLOGY (2012)
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
Shigeki Chiba et al.
NATURE IMMUNOLOGY (2012)
Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion
Manu Rangachari et al.
NATURE MEDICINE (2012)
Ipilimumab in advanced melanoma: reports of long-lasting responses
Alberto Farolfi et al.
MELANOMA RESEARCH (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Camouflage and sabotage: tumor escape from the immune system
Isabel Poschke et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Li Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
Dallas B. Flies et al.
JOURNAL OF IMMUNOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Omar S. Qureshi et al.
SCIENCE (2011)
Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
Ryosuke Hino et al.
CANCER (2010)
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
Xingxing Zang et al.
MODERN PATHOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer-Preclinical Background: CTLA-4 and PD-1 Blockade
Jeffrey Weber
SEMINARS IN ONCOLOGY (2010)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay
Vidya Kondadasula et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Targeting the TCR signaling checkpoint: a therapeutic strategy to reactive memory T cells in the tumor microenvironment
Michelle R. Simpson-Abelson et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum
Guangbo Zhang et al.
IMMUNOLOGY (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells
Ana C. Anderson et al.
SCIENCE (2007)
Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter
Heather M. Gibson et al.
JOURNAL OF IMMUNOLOGY (2007)
Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas
B. Falini et al.
LEUKEMIA (2007)
Reversal of the TCR stop signal by CTLA-4
Helga Schneider et al.
SCIENCE (2006)
Human papillomavirus vaccines
Margaret A. Stanley
REVIEWS IN MEDICAL VIROLOGY (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Paradoxical effects of interleukin-10 on the maturation of murine myeloid dendritic cells
DL Commeren et al.
IMMUNOLOGY (2003)
Mouse B7-H3 induces antitumor immunity
X Sun et al.
GENE THERAPY (2003)
Control of regulatory T cell development by the transcription factor Foxp3
S Hori et al.
SCIENCE (2003)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)
Structural analysis of CTLA-4 function in vivo
EL Masteller et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
